Andrew Chen

US Patent:

7229630, Jun 12, 2007

Filed:

Jun 20, 2003

Appl. No.:

10/465810

Inventors:

Andrew X. Chen - San Diego CA, US
Julius Knowles - Del Mar CA, US
Eckard Weber - San Diego CA, US

Assignee:

Novalar Pharmaceuticals, Inc. - DE

International Classification:

A61K 9/08
A61K 47/12
A61K 47/18

US Classification:

424400, 424423, 514784, 514788

Abstract:

The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.

US Patent:

7569230, Aug 4, 2009

Filed:

Dec 15, 2006

Appl. No.:

11/611504

Inventors:

Andrew X Chen - San Diego CA, US
Julius Knowles - Del Mar CA, US
Eckard Weber - San Diego CA, US

Assignee:

Novalar Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 9/08
A61K 31/417
A61K 31/497
A61K 47/12
A61K 47/16
A61K 47/26

US Classification:

424400, 51425216, 514401, 514818

Abstract:

The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.

US Patent:

7575757, Aug 18, 2009

Filed:

Mar 18, 2005

Appl. No.:

11/082968

Inventors:

Andrew X. Chen - San Diego CA, US
Julius Knowles - Del Mar CA, US
Eckard Weber - San Diego CA, US

Assignee:

Novalar Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 9/08
A61K 31/417
A61K 31/497
A61K 47/12
A61K 47/16
A61K 47/26

US Classification:

424400, 51425216, 514401, 514818

Abstract:

The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.

US Patent:

7871632, Jan 18, 2011

Filed:

Jul 12, 2004

Appl. No.:

10/889226

Inventors:

Andrew Xian Chen - San Diego CA, US

Assignee:

Adventrx Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 9/00

US Classification:

424400

Abstract:

The present invention provides compositions for delivering highly water-soluble drugs (such as vinca alkaloids) and methods of using such compositions.

US Patent:

7944251, May 17, 2011

Filed:

Mar 9, 2009

Appl. No.:

12/381227

Inventors:

Andrew Chen - Redondo Beach CA, US
Joseph Aziz - Irvine CA, US
Derek Tam - Irvine CA, US

Assignee:

Broadcom Corporation - Irvine CA

International Classification:

H03B 1/00

US Classification:

327108, 327109, 327512

Abstract:

According to one exemplary embodiment, a transmitter module includes a line drive including a current digital-to-analog converter, where the line driver provides an analog output waveform. The current digital-to-analog converter receives a digitally filtered input waveform including at least two voltage steps. The at least two voltage steps of the digitally filtered input waveform cause a rise time of the analog output waveform to have a reduced dependency on process, voltage, and temperature variations in the line driver, while meeting stringent rise time requirements. The digitally filtered input waveform has an initial voltage level and a final voltage level, where the final voltage level is substantially equal to a sum of the at least two voltage steps of the digitally filtered input waveform.

US Patent:

7968122, Jun 28, 2011

Filed:

Dec 3, 2004

Appl. No.:

11/003302

Inventors:

Andrew Xian Chen - San Diego CA, US

Assignee:

Adventrx Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 9/14

US Classification:

424484

Abstract:

The present invention provides antiviral compositions that comprise one or more of an ionic multivalent metal component, a cationic polymer, and a cationic surfactant. The present invention also provides methods for making and using such antiviral compositions.

US Patent:

7982491, Jul 19, 2011

Filed:

Apr 8, 2009

Appl. No.:

12/384793

Inventors:

Joseph Aziz - Irvine CA, US
Andrew Chen - Redondo Beach CA, US
Derek Tam - Irvine CA, US
Agnes Neves Woo - Encino CA, US
Marcel Lugthart - Aliso Viejo CA, US

Assignee:

Broadcom Corporation - Irvine CA

International Classification:

H03K 17/16
H03K 19/003

US Classification:

326 30, 326 34, 326 86

Abstract:

According to one exemplary embodiment, an active termination circuit includes at least one active termination branch, where the at least one active termination branch includes at least one transistor for providing an active termination output. The at least one active termination branch further includes an amplifier driving the at least one transistor, where the amplifier has a non-inverting input coupled to the active termination output via a feedback network. The amplifier controls a current flowing through the at least one transistor so as to provide the active termination output. The active termination output can be provided at a drain of the at least one transistor, where a source of the at least one transistor is coupled to ground through a degeneration transistor and a tail current sink.

US Patent:

8026250, Sep 27, 2011

Filed:

Dec 10, 2010

Appl. No.:

12/965676

Inventors:

Andrew Xian Chen - San Diego CA, US

Assignee:

Adventrx Pharmaceuticals, Inc. - San Diego CA

International Classification:

A01N 43/42
A61K 31/44
A61K 9/00

US Classification:

514283, 424400

Abstract:

The present invention provides compositions for delivering highly water-soluble drugs (such as alkaloids) and methods of using such compositions.